Vi­a­Cyte adds to the war chest in what looks like an IPO-bound ef­fort to bring re­gen­er­a­tive med­i­cine to di­a­betes

Stem cell ther­a­pies have long held promise if pro­vid­ing cu­ra­tive an­swers to chron­ic dis­ease, but the field has tak­en decades to bear fruit de­spite some big hopes. A long ges­tat­ing biotech out of San Diego thinks it has the se­cret sauce to cure type 1 di­a­betes, and now it’s rak­ing in piles of cash with the po­ten­tial for a ma­jor IPO in the off­ing.

Vi­a­Cyte has closed an ad­di­tion­al $45 mil­lion tranche for its Se­ries D, bring­ing its to­tal fundraise for the round to $115 mil­lion with the back­ing of a slate of crossover in­vestors that ap­pear to spell a loom­ing IPO for the long-lived re­gen­er­a­tive med­i­cine play­er, the com­pa­ny said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER